印度婴儿接种单价轮状病毒疫苗(Rotavac)后肠套叠风险:自身对照病例系列分析
该研究在印度16个邦22家医院开展主动前瞻性肠套叠监测,采用自身对照病例系列(SCCS)方法分析52名确认接种Rotavac的婴儿。结果显示,接种任何剂次后21天内肠套叠风险未高于背景风险,但分析样本量有限。
要点
- 接种Rotavac后21天内肠套叠风险未显著升高
- 第1剂后21天内未观察到肠套叠病例
- 第3剂后8-21天相对发病率为2.52(95%CI 0.78-5.61)
核心结论
- 基于52名婴儿的有限SCCS分析,印度婴儿接种Rotavac后21天内肠套叠风险未高于背景风险。
研究设计与样本
- 2016年4月至2017年9月在印度16个邦22家医院开展主动前瞻性肠套叠监测。
- 采用自身对照病例系列(SCCS)方法,纳入28-364日龄、Brighton协作组1级病例且确认接种轮状病毒疫苗的52名婴儿。
主要发现
- 670名2-23月龄肠套叠患儿中,311名(46.4%)为28-364日龄且疫苗接种状态确认。
- 第1剂后21天内未观察到肠套叠病例;第2剂后8-21天仅1例;第3剂后1-7天2例、8-21天7例。
- 第1、2剂后1-7天未见病例,第3剂后1-7天相对发病率1.71(95%CI 0.0-5.11)。
- 第1剂后8-21天未见病例,第2剂后8-21天相对发病率0.71(95%CI 0.0-3.28),第3剂后8-21天相对发病率2.52(95%CI 0.78-5.61)。
临床怎么用
- 在印度婴儿中接种Rotavac后21天内未观察到肠套叠风险升高,支持继续推广接种。
- 临床应继续监测接种后肠套叠症状,尤其在第3剂后8-21天。
局限性
- SCCS分析仅纳入52名儿童,样本量有限,结果需更大规模研究验证。
- 仅纳入Brighton协作组1级病例,可能低估轻症肠套叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An association between rotavirus vaccination and intussusception has been documented in post-licensure studies in some countries. We evaluated the risk of intussusception associated with monovalent rotavirus vaccine (Rotavac) administered at 6, 10 and 14 weeks of age in India. METHODS: Active prospective surveillance for intussusception was conducted at 22 hospitals across 16 states from April 2016 through September 2017. Data on demography, clinical features and vaccination were documented. Age-adjusted relative incidence for 1-7, 8-21, and 1-21 days after rotavirus vaccination in children aged 28-364 days at intussusception onset was estimated using the self-controlled case-series (SCCS) method. Only Brighton Collaboration level 1 cases were included. RESULTS: Out of 670 children aged 2-23 months with intussusception, 311 (46.4%) children were aged 28-364 days with confirmed vaccination status. Out of these, 52 intussusception cases with confirmed receipt of RVV were included in the SCCS analysis. No intussusception case was observed within 21 days of dose 1. Only one case occurred during 8-21 days after the dose 2. Post-dose 3, two cases in 1-7 days and 7 cases during 8-21 days period were observed. There was no increased risk of intussusception during 1-7 days after the doses 1 and 2 (zero cases observed) or dose 3 (relative incidence [RI], 1.71 [95% confidence interval {CI} 0.0-5.11]). Similarly, no increased risk during 8-21 days after the dose 1 (zero cases observed), dose 2 (RI, 0.71 [95% CI, 0.0-3.28]) or dose 3 (RI, 2.52 [95% CI, 0.78-5.61]). The results were similar for 1-21 day periods after the doses separately or pooled. CONCLUSIONS: The risk of intussusception during the first 21 days after any dose of rotavirus vaccine (Rotavac) was not higher among the Indian infants than the background risk, based on limited SCCS analysis of 52 children.
引用
- Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis. Vaccine. 2020. PMID: 32972735. doi:10.1016/j.vaccine.2020.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。